Khiron Life Sciences Grants Options & Restricted Stock To Company Officers, Announces Conference Participation

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a medical and cosmetic cannabis products and treatment firm with operations in Latin America & Europe has announced the award of stock options and restricted share units under the company’s amended and restated restricted share unit plans approved by shareholders at the annual general and special meeting of shareholders held on September 10, 2020.

On November 23, 2021, the board of directors granted a total of 1,400,000 options and 950,000 restricted stock units to certain officers of the company. Certain of the options and restricted stock units are subject to performance-based vesting conditions. The options are exercisable at a price of $0.75 per share and will expire on November 23, 2026. Unvested restricted stock units will expire on December 15, 2024.

Khiron has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico. The company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with a diverse executive team and board of directors.

Khiron to Participate in the Lytham Partners Winter 2021 Investor Conference

Khiron also announced today its CEO, Alvaro Torres will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the company will be participating in a webcasted Fireside Chat discussing its vision for 2022 and conducting 1×1 virtual investor meetings.

The webcasted Fireside Chat will be available for viewing at 11:00am ET on Monday, December 13, 2021 on the Company’s website at https://investors.khiron.ca/investor-information or https://wsw.com/webcast/lytham3/khrn/2039430. The webcast will also be available for replay following the event.